Abstract
Doxorubicin (Dox) is widely used in cancer therapy, but the clinical application is limited by its cardiotoxicity. The underlying mechanism of Dox-induced cardiotoxicity remains unclear. Present study aimed to evaluate the role of NLRP3 inflammasome in Dox-induced cardiotoxicity. The NLRP3 inflammasome was activated in the myocardium of Dox-treating (5 mg/kg, once every other day, cumulative dosage to 15 mg/kg and sacrificed after 2 days of last Dox injection) C57BL/6 mice as shown by the up-regulation of NLRP3 and Caspase-1 p20. Dox (1 μM for 48 h) induced the apoptosis of H9c2 cells and primary cardiomyocytes concomitantly with up-regulation of NLRP3, ASC and Caspase-1 p20 expressions, as well as the increased IL-1β secretion, suggesting the activation of NLRP3 inflammasome. These effects of Dox on H9c2 cells and primary cardiomyocytes can be reversed by MCC950, a specific inhibitor of NLRP3. In view of the key role of ROS on the Dox-induced cardiotoxicity, the relationship between ROS and NLRP3 was further investigated. The ROS level was increased in myocardium, H9c2 cells and primary cardiomyocytes after treating with Dox. Decreasing ROS level by NAC can inhibit the NLRP3 inflammasome activation, secretion of IL-1β and apoptosis in Dox-treating H9c2 cells and primary cardiomyocytes. Collectively, this study reveals a crucial role of ROS/NLRP3-associated inflammasome activation in Dox-induced cardiotoxicity, and NLRP3 inflammasome may represent a new therapeutic target for Dox-induced cardiotoxicity.
Graphic Abstract
Similar content being viewed by others
References
Cagel, M., Grotz, E., Bernabeu, E., Moretton, M. A., & Chiappetta, D. A. (2017). Doxorubicin: Nanotechnological overviews from bench to bedside. Drug Discovery Today, 22, 270–281.
Renu, K., Abilash, V. G., & Arunachalam, S. (2018). Molecular mechanism of doxorubicin-induced cardiomyopathy—An update. European Journal of Pharmacology, 818, 241–253.
Caram, M. E. V., Guo, C., Leja, M., Smerage, J., Henry, N. L., Giacherio, D., et al. (2015). Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancer. Breast Cancer Research and Treatment, 152, 163–172.
Xin, Y. F., Zhou, G. L., Shen, M., Chen, Y. X., Liu, S. P., Chen, G. C., et al. (2007). Angelica sinensis: A novel adjunct to prevent doxorubicin-induced chronic cardiotoxicity. Basic & Clinical Pharmacology & Toxicology, 101, 421–426.
Zhang, X., Hu, C., Kong, C. Y., Song, P., Wu, H. M., Xu, S. C., et al. (2020). FNDC5 alleviates oxidative stress and cardiomyocyte apoptosis in doxorubicin-induced cardiotoxicity via activating AKT. Cell Death and Differentiation, 27, 540–555.
Yu, S., Wang, D., Huang, L., Zhang, Y., Luo, R., Adah, D., et al. (2019). The complement receptor C5aR2 promotes protein kinase R expression and contributes to NLRP3 inflammasome activation and HMGB1 release from macrophages. The Journal of Biological Chemistry, 294, 8384–8394.
Ren, G., Zhang, X., Xiao, Y., Zhang, W., Wang, Y., Ma, W., et al. (2019). ABRO1 promotes NLRP3 inflammasome activation through regulation of NLRP3 deubiquitination. The EMBO Journal. https://doi.org/10.15252/embj.2018100376.
Baroja-Mazo, A., Martin-Sanchez, F., Gomez, A. I., Martinez, C. M., Amores-Iniesta, J., Compan, V., et al. (2014). The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. Nature Immunology, 15, 738–748.
Liu, D., Zeng, X., Li, X., Mehta, J. L., & Wang, X. (2018). Role of NLRP3 inflammasome in the pathogenesis of cardiovascular diseases. Basic Research in Cardiology, 113, 5.
Minutoli, L., Puzzolo, D., Rinaldi, M., Irrera, N., Marini, H., Arcoraci, V., et al. (2016). ROS-Mediated NLRP3 Inflammasome activation in brain, heart, kidney, and testis ischemia/reperfusion Injury. Oxidative Medicine and Cellular Longevity, 2016, 2183026.
Jin, Y., & Fu, J. (2019). Novel insights into the NLRP 3 inflammasome in atherosclerosis. Journal of the American Heart Association, 8, e012219.
Luo, B., Huang, F., Liu, Y., Liang, Y., Wei, Z., Ke, H., et al. (2017). NLRP3 Inflammasome as a molecular marker in diabetic cardiomyopathy. Frontiers in Physiology, 8, 519.
Abais, J. M., Xia, M., Zhang, Y., Boini, K. M., & Li, P. L. (2015). Redox regulation of NLRP3 inflammasomes: ROS as trigger or effector? Antioxidants & Redox Signaling, 22, 1111–1129.
Songbo, M., Lang, H., Xinyong, C., Bin, X., Ping, Z., & Liang, S. (2019). Oxidative stress injury in doxorubicin-induced cardiotoxicity. Toxicology Letters, 307, 41–48.
Li, W., Zhang, Z., Li, X., Cai, J., Li, D., Du, J., et al. (2019). CGRP derived from cardiac fibroblasts is an endogenous suppressor of cardiac fibrosis. Cardiovascular Research. https://doi.org/10.1093/cvr/cvz234.
Li, W. Q., Li, X. H., Wu, Y. H., Du, J., Wang, A. P., Li, D., et al. (2016). Role of eukaryotic translation initiation factors 3a in hypoxia-induced right ventricular remodeling of rats. Life Sciences, 144, 61–68.
Wei, S., Sun, T., Du, J., Zhang, B., Xiang, D., & Li, W. (2018). Xanthohumol, a prenylated flavonoid from Hops, exerts anticancer effects against gastric cancer in vitro. Oncology Reports, 40, 3213–3222.
Chen, G. Y., & Nunez, G. (2010). Sterile inflammation: Sensing and reacting to damage. Nature Reviews Immunology, 10, 826–837.
Latz, E., Xiao, T. S., & Stutz, A. (2013). Activation and regulation of the inflammasomes. Nature Reviews Immunology, 13, 397–411.
Mezzaroma, E., Toldo, S., Farkas, D., Seropian, I. M., Van Tassell, B. W., Salloum, F. N., et al. (2011). The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proceedings of the National Academy of Sciences of the United States of America, 108, 19725–19730.
Kawaguchi, M., Takahashi, M., Hata, T., Kashima, Y., Usui, F., Morimoto, H., et al. (2011). Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation, 123, 594–604.
Lou, H., Danelisen, I., & Singal, P. K. (2005). Involvement of mitogen-activated protein kinases in adriamycin-induced cardiomyopathy. American Journal of Physiology Heart and Circulatory Physiology, 288, H1925–1930.
Maier, H. J., Schips, T. G., Wietelmann, A., Kruger, M., Brunner, C., Sauter, M., et al. (2012). Cardiomyocyte-specific IkappaB kinase (IKK)/NF-kappaB activation induces reversible inflammatory cardiomyopathy and heart failure. Proceedings of the National Academy of Sciences of the United States of America, 109, 11794–11799.
De Luca, G., Cavalli, G., Campochiaro, C., Tresoldi, M., & Dagna, L. (2018). Myocarditis: An Interleukin-1-mediated disease? Frontiers in Immunology, 9, 1335.
Kraft, L., Erdenesukh, T., Sauter, M., Tschope, C., & Klingel, K. (2019). Blocking the IL-1beta signalling pathway prevents chronic viral myocarditis and cardiac remodeling. Basic Research in Cardiology, 114, 11.
Sho, T., & Xu, J. (2019). Role and mechanism of ROS scavengers in alleviating NLRP3-mediated inflammation. Biotechnology and Applied Biochemistry, 66, 4–13.
Goffart, S., von Kleist-Retzow, J. C., & Wiesner, R. J. (2004). Regulation of mitochondrial proliferation in the heart: Power-plant failure contributes to cardiac failure in hypertrophy. Cardiovascular Research, 64, 198–207.
Tang, Y. S., Zhao, Y. H., Zhong, Y., Li, X. Z., Pu, J. X., Luo, Y. C., et al. (2019). Neferine inhibits LPS-ATP-induced endothelial cell pyroptosis via regulation of ROS/NLRP3/Caspase-1 signaling pathway. Inflammation Research, 68, 727.
Xu, M., Wang, L., Wang, M., Wang, H., Zhang, H., Chen, Y., et al. (2019). Mitochondrial ROS and NLRP3 inflammasome in acute ozone-induced murine model of airway inflammation and bronchial hyperresponsiveness. Free Radical Research, 53, 1–11.
Li, W., He, W., Xia, P., Sun, W., Shi, M., Zhou, Y., et al. (2019). Total extracts of Abelmoschus manihot L. attenuates adriamycin-induced renal tubule injury via suppression of ROS-ERK1/2-mediated NLRP3 inflammasome activation. Frontiers in Pharmacology, 10, 567.
Acknowledgements
This work was supported by Grants of the National Natural Scientific Foundation of China (Nos. 81703518, 81973406, 81773734, 81701577), Hunan Provincial Natural Scientific Foundation (Nos. 2018JJ3571, 2019JJ50849, 2020JJ4823), Fundamental Research Funds for the Central Universities of Central South University (No. 2020zzts822), and Scientific Research Project of Hunan Provincial Health and Family Planning Commission (No. B20180253).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Additional information
Handling Editor: Yu-Ming Kang.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Wei, S., Ma, W., Li, X. et al. Involvement of ROS/NLRP3 Inflammasome Signaling Pathway in Doxorubicin-Induced Cardiotoxicity. Cardiovasc Toxicol 20, 507–519 (2020). https://doi.org/10.1007/s12012-020-09576-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12012-020-09576-4